Abstract
Introduction: Xia-Gibbs syndrome (OMIM 615829) is a rare developmental disorder, caused by heterozygous de novo variants in the AHDC1 gene. Hallmark features include global developmental delay, facial dysmorphisms, and behavioral problems. To date, more than 250 individuals have been diagnosed worldwide. Case Report: We report a 13-year-old female who, in association with typical features of Xia-Gibbs syndrome, presented with macrocrania, pes cavus, and conjunctival melanosis. Whole-exome sequencing identified a de novo frameshift variant, which had not been reported in the literature before. Conclusion: We summarized the main clinical and phenotypic features of patients described in the literature, and in addition, we discuss another feature found in our patient and observed in other cases described, eye asymmetry, which has never been highlighted, and suggest that it could be part of the typical clinical presentation of this condition.
Journal Section:
Novel Insights from Clinical Practice
References
1.
Cardoso-Dos-Santos AC, Oliveira Silva T, Silveira Faccini A, Woycinck Kowalski T, Bertoli-Avella A, Morales Saute JA, et al. Novel AHDC1 gene mutation in a Brazilian individual: implications of xia-gibbs syndrome. Mol Syndromol. 2020;11(1):24–9.
2.
Cheng X, Tang F, Hu X, Li H, Li M, Fu Y, et al. Two Chinese Xia-Gibbs syndrome patients with partial growth hormone deficiency, Mol Genet Genomic. Med. 2019 Apr;7(4):e00596.
3.
Della Vecchia S, Milone R, Cagiano R, Calderoni S, Santocchi E, Pasquariello R, et al. Focusing on autism spectrum disorder in xia – gibbs syndrome: description of a female with high functioning autism and literature review. Children. 2021;8(6):450.
4.
Díaz-Ordoñez L, Ramirez-Montaño D, Candelo E, Cruz S, Pachajoa H. Syndromic intellectual disability caused by a novel truncating variant in AHDC1: a case report. Iran J Med Sci. 2019;44(3):257–61.
5.
Faergeman SL, Bojesen AB, Rasmussen M, Becher N, Andreasen L, Andersen BN, et al. Phenotypic heterogeneity and mosaicism in Xia-Gibbs syndrome: five Danish patients with novel variants in AHDC1. Eur J Med Genet. 2021 Sep;64(9):104280.
6.
Garcia-Acero M, Acosta J. Whole-Exome Sequencing Identifies a de novo AHDC1 Mutation in a Colombian Patient with Xia-Gibbs Syndrome. Mol Syndromol. 2017;8(6):308–12.
7.
Goyal C, Naqvi WM, Sahu A, Aujla AS. Xia-Gibbs syndrome: a rare case report of a male child and insight into physiotherapy management. Cureus. 2020 Aug 9;12(8):e9622.
8.
Gumus E. Extending the phenotype of Xia-Gibbs syndrome in a two-year-old patient with craniosynostosis with a novel de novo AHDC1 missense mutation. Eur J Med Genet. 2020 Jan;63(1):103637.
9.
Jiang Y, Wangler MF, McGuire AL, Lupski JR, Posey JE, Khayat MM, et al. The phenotypic spectrum of Xia-Gibbs syndrome. Am J Med Genet A. 2018;176(6):1315–26.
10.
Khayat M, Hu J, Jiang Y, Li H, Chander V, Dawood M, et al. AHDC1 missense mutations in Xia-Gibbs syndrome. HGG Adv. 2021a;2(4):100049.
11.
Khayat M, Li H, Chander V, Hu J, Hansen AW, Li S, et al. Phenotypic and protein localization heterogeneity associated with AHDC1 pathogenic protein-truncating alleles in Xia-Gibbs syndrome. Hum Mutat. 2021b;42(5):577–91.
12.
Mubungu G, Makay P, Boujemla B, Yanda S, Posey JE, Lupski JR, et al. Clinical presentation and evolution of Xia-Gibbs syndrome due to p.Gly375ArgfsTer3 variant in a patient from DR Congo (Central Africa). Am J Med Genet A. 2021 Mar;185(3):990–4.
13.
Murdock DR, Jiang Y, Wangler M, Khayat MM, Sabo A, Juusola J, et al. Xia-Gibbs syndrome in adulthood: a case report with insight into the natural history of the condition. Cold Spring Harb Mol Case Stud. 2019 Jun 3;5(3):a003608.
14.
Oellers P, Karp CL. Management of pigmented conjunctival lesions. Ocul Surf. 2012;10(4):251–63.
15.
Park HY, Kim M, Jang W, Jang DH. Phenotype of a patient with a 1p36.11-p35.3 interstitial deletion encompassing the AHDC1. Ann Lab Med. 2017;37(6):563–5.
16.
Popp B, Ekici AB, Thiel CT, Hoyer J, Wiesener A, Kraus C, et al. Exome Pool-Seq in neurodevelopmental disorders. Eur J Hum Genet. 2017;25(12):1364–76. 29158550.
17.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the association for molecular Pathology. Genet Med. 2015;17(5):405–24.
18.
Ritter AL, McDougall C, Skraban C, Medne L, Bedoukian EC, Asher SB, et al. Variable clinical manifestations of xia-Gibbs syndrome: findings of consecutively identified cases at a single children’s hospital. Am J Med Genet A. 2018;176(9):1890–6.
19.
Shields CL, Shields JA. Tumors of the conjunctiva and cornea. Surv Ophthalmol. 2004;49(1):3–24.
20.
Talevich E, Shain AH, Botton T, Bastian B. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol. 2016;12(4):e1004873.
21.
Wan XQ, Zeng F, Huang XF, Yang HQ, Wang L, Shi YC, et al. Risperidone stimulates food intake and induces body weight gain via the hypothalamic arcuate nucleus 5-HT2c receptor NPY pathway. CNS Neurosci Ther. 2020 May;26(5):558–66.
22.
Wang Q, Huang X, Liu Y, Peng Q, Zhang Y, Liu J, et al. Microdeletion and microduplication of 1p36.11p35.3 involving AHDC1 contribute to neurodevelopmental disorder. Eur J Med Genet. 2020 Jan;63(1):103611.
23.
Xia F, Bainbridge MN, Tan TY, Wangler MF, Scheuerle AE, Zackai EH, et al. De novo truncating mutations in AHDC1 in individuals with syndromic expressive language delay, hypotonia, and sleep apnea. Am J Hum Genet. 2014;94(5):784–9.
24.
Yang H, Douglas G, Monaghan KG, Retterer K, Cho MT, Escobar LF, et al. De novo truncating variants in the AHDC1 gene encoding the AT-hook DNA-binding motif-containing protein 1 are associated with intellectual disability and developmental delay. Cold Spring Harb Mol Case Stud. 2015;1:a000562.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
